MGMT-Unmethylated Glioblastoma Clinical Trial
Official title:
Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Newly Diagnosed MGMT Promotor Unmethylated Glioblastoma
Temozolomide provided significant and clinically meaningful benefit in MGMT gene promoter methylation glioblastoma. However, in unmethylated patients, the effect of Temozolomide is limited. The aim of this study is to compare the effect of Etoposide plus Cisplatin and Temozolomide in patients with MGMT gene promoter unmethylation glioblastoma.
60 Patients with glioblastoma were recruited for this study based on the following eligibility criteria: Age between 18 and 70, performance status of 0-1 (Eastern Cooperative Oncology Group performance status), histologically confirmed MGMT gene promoter unmethylation glioblastoma, no cerebrospinal fluid and distant metastatic disease. All patients had adequate hematologic, hepatic, and renal function. Patients younger than 18 years; patients with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities were excluded. 60 patients were randomly divided into two groups and compared the difference of efficacy between the two groups ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05033587 -
Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.
|
Phase 2 | |
| Active, not recruiting |
NCT04396860 -
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06186401 -
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
|
Phase 1 | |
| Terminated |
NCT03250299 -
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
|
Phase 1 | |
| Recruiting |
NCT03107780 -
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
|
Phase 1 | |
| Recruiting |
NCT05909618 -
Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
|
Phase 2 | |
| Recruiting |
NCT04725214 -
Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma
|
Phase 2 | |
| Not yet recruiting |
NCT05879250 -
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
|
Phase 2 | |
| Recruiting |
NCT04224441 -
Repurposing Chlorpromazine in the Treatment of Glioblastoma
|
Phase 2 | |
| Recruiting |
NCT05236036 -
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
|
Phase 1 | |
| Active, not recruiting |
NCT03452930 -
Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma
|
Phase 1 |